Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » a decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
c decrease » c decreased (Expand Search), a decrease (Expand Search), rc decreased (Expand Search)
_ decrease » _ decreased (Expand Search)
e fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
5 c » 25 c (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » a decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
c decrease » c decreased (Expand Search), a decrease (Expand Search), rc decreased (Expand Search)
_ decrease » _ decreased (Expand Search)
e fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
5 c » 25 c (Expand Search)
-
1
-
2
-
3
Clinical characteristics of patients in the increased-, stable-, and decreased-RPR groups.
Published 2023Subjects: -
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells.
Published 2019“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). (B) Following 24 hours of treatment with FTY720, the proliferation of HuH6 cells measured using the CellTiter 96 cell proliferation assay was significantly decreased (IC<sub>50</sub> = 6.4 μM, p ≤ 0.05). …”
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
Downregulation of DOM decreases the abundance of PER and TIM.
Published 2019“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”
-
20
mGluR5 receptor decreased glycinergic currents.
Published 2019“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”